Trial Profile
Phase I/II Study of Carboplatin and Pralatrexate in Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Pralatrexate (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- 20 Dec 2017 Status changed from active, no longer recruiting to completed.
- 15 Nov 2016 Results (n=50) published in the Cancer.
- 15 Jul 2016 Results published in the Cancer.